tiprankstipranks
Advertisement
Advertisement

ANRO Stock Latest News

Alto Neuroscience price target lowered to $36 from $38 at Baird
The FlyAlto Neuroscience price target lowered to $36 from $38 at Baird
1d ago
ANRO
Alto Neuroscience price target raised to $24 from $21 at Wedbush
PremiumThe Fly
Alto Neuroscience price target raised to $24 from $21 at Wedbush
5d ago
ANRO
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
PremiumRatings
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
5d ago
ANRO
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
PremiumRatings
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
5d ago
ANRO
Alto Neuroscience Shareholders Shape Governance and Equity Plans
PremiumCompany Announcements
Alto Neuroscience Shareholders Shape Governance and Equity Plans
6d ago
8K
ANRO
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
PremiumThe FlyAlto Neuroscience reports Q1 EPS (80c) vs (56c) last year
6d ago
ANRO
Alto Neuroscience initiated with a Buy at BofA
Premium
The Fly
Alto Neuroscience initiated with a Buy at BofA
15d ago
ANRO
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
Premium
The Fly
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
15d ago
ANRO
Alto Neuroscience participates in a conference call with H. C. Wainwright
PremiumThe Fly
Alto Neuroscience participates in a conference call with H. C. Wainwright
20d ago
ANRO
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
PremiumThe Fly
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
28d ago
ANRO
Alto Neuroscience files to sell 6M shares of common stock for holders
PremiumThe Fly
Alto Neuroscience files to sell 6M shares of common stock for holders
1M ago
ANRO
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
PremiumThe Fly
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
2M ago
ANRO
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
PremiumThe FlyAlto Neuroscience price target lowered to $21 from $22 at Wedbush
2M ago
ANRO
Morning Movers: Immunovant sinks after batoclimab trials miss goal
Premium
The Fly
Morning Movers: Immunovant sinks after batoclimab trials miss goal
2M ago
BP
ALK
Alto Neuroscience price target lowered to $38 from $41 at Baird
Premium
The Fly
Alto Neuroscience price target lowered to $38 from $41 at Baird
2M ago
ANRO
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
PremiumThe Fly
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
2M ago
ANRO
Closing Bell Movers: Globalstar spikes on acquisition report
PremiumThe Fly
Closing Bell Movers: Globalstar spikes on acquisition report
2M ago
FC
AMZN
Alto Shifts Focus to ALTO-207 After ALTO-101 Data
PremiumCompany Announcements
Alto Shifts Focus to ALTO-207 After ALTO-101 Data
2M ago
8K
ANRO
Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback
PremiumRatings
Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback
2M ago
ANRO
Alto Neuroscience announces ALTO-101 did not achieve statistical significance
PremiumThe FlyAlto Neuroscience announces ALTO-101 did not achieve statistical significance
2M ago
ANRO
Alto Neuroscience price target raised to $41 from $22 at Baird
Premium
The Fly
Alto Neuroscience price target raised to $41 from $22 at Baird
2M ago
ANRO
Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
Premium
Ratings
Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
2M ago
ANRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >